Drug Type Biosimilar, Monoclonal antibody |
Synonyms GNR-093, GNR093 |
Target |
Mechanism CD49d antagonists(Integrin alpha-4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 3 | RU | 06 Feb 2023 |